118 related articles for article (PubMed ID: 37909978)
1. Importance of Progression-free Survival in Second-line Chemotherapy in Patients With Advanced or Recurrent Gastric Cancer.
Sano A; Sohda M; Hosoi N; Tateno K; Watanabe T; Uchida S; Nakazawa N; Osone K; Okada T; Shiraishi T; Sakai M; Ogawa H; Shirabe K; Saeki H
Anticancer Res; 2023 Nov; 43(11):5205-5213. PubMed ID: 37909978
[TBL] [Abstract][Full Text] [Related]
2. Prognostic significance of a systemic inflammatory response in patients receiving first-line palliative chemotherapy for recurred or metastatic gastric cancer.
Hwang JE; Kim HN; Kim DE; Choi HJ; Jung SH; Shim HJ; Bae WK; Hwang EC; Cho SH; Chung IJ
BMC Cancer; 2011 Nov; 11():489. PubMed ID: 22103888
[TBL] [Abstract][Full Text] [Related]
3. Progression-free survival in first-line chemotherapy is a prognostic factor in second-line chemotherapy in patients with advanced gastric cancer.
Hashimoto K; Takashima A; Nagashima K; Okazaki SS; Nakajima TE; Kato K; Hamaguchi T; Yamada Y; Shimada Y
J Cancer Res Clin Oncol; 2010 Jul; 136(7):1059-64. PubMed ID: 20037789
[TBL] [Abstract][Full Text] [Related]
4. Post progression survival analysis of metastatic gastric and gastroesophageal junction cancer patients after second-line treatment.
Turkmen E; Erdogan B; Kodaz H; Hacibekiroglu I; Onal Y; Uzunoglu S; Kilic N; Cicin I
Acta Gastroenterol Belg; 2016; 79(2):211-5. PubMed ID: 27382940
[TBL] [Abstract][Full Text] [Related]
5. Second-line chemotherapy using taxane in patients with advanced gastric cancer who presented with severe peritoneal metastasis: a multicenter retrospective study.
Arai H; Kawahira M; Yasui H; Masuishi T; Muro K; Nakajima TE
Int J Clin Oncol; 2021 Feb; 26(2):355-363. PubMed ID: 33063177
[TBL] [Abstract][Full Text] [Related]
6. Weekly paclitaxel plus ramucirumab versus weekly nab-paclitaxel plus ramucirumab for unresectable advanced or recurrent gastric cancer with peritoneal dissemination refractory to first-line therapy-the P-SELECT trial (WJOG10617G)-a randomised phase II trial by the West Japan Oncology Group.
Hirata K; Hamamoto Y; Ando M; Imamura CK; Yoshimura K; Yamazaki K; Hironaka S; Muro K
BMC Cancer; 2020 Jun; 20(1):548. PubMed ID: 32532230
[TBL] [Abstract][Full Text] [Related]
7. Apatinib combined with S-1 as second-line therapy in advanced gastric cancer.
Qiu ZY; Qin R; Tian GY; Zhang Z; Chen M; He H; Xi Y; Wang Y
Medicine (Baltimore); 2021 Apr; 100(17):e25630. PubMed ID: 33907117
[TBL] [Abstract][Full Text] [Related]
8. Salvage systemic therapy for advanced gastric and oesophago-gastric junction adenocarcinoma.
Tomita Y; Moldovan M; Chang Lee R; Hsieh AH; Townsend A; Price T
Cochrane Database Syst Rev; 2020 Nov; 11(11):CD012078. PubMed ID: 33210731
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of taxane monotherapy in advanced gastric cancer refractory to triplet chemotherapy with docetaxel, cisplatin, and S-1: a multicenter retrospective study.
Iizumi S; Takashima A; Narita Y; Tajika M; Muro K; Kawai S; Yasui H; Matsushima T; Takahari D; Nagashima K; Boku N
Cancer Chemother Pharmacol; 2017 Sep; 80(3):575-582. PubMed ID: 28730292
[TBL] [Abstract][Full Text] [Related]
10. Progression-free survival and post-progression survival in patients with advanced gastric cancer treated with first-line chemotherapy.
Shitara K; Matsuo K; Muro K; Doi T; Ohtsu A
J Cancer Res Clin Oncol; 2013 Aug; 139(8):1383-9. PubMed ID: 23708301
[TBL] [Abstract][Full Text] [Related]
11. A retrospective analysis of second-line chemotherapy in patients with advanced gastric cancer.
Ji SH; Lim DH; Yi SY; Kim HS; Jun HJ; Kim KH; Chang MH; Park MJ; Uhm JE; Lee J; Park SH; Park JO; Park YS; Lim HY; Kang WK
BMC Cancer; 2009 Apr; 9():110. PubMed ID: 19358705
[TBL] [Abstract][Full Text] [Related]
12. Palliative chemotherapy for gastroesophageal cancer in old and very old patients: A retrospective cohort study at the National Center for Tumor Diseases, Heidelberg.
Berger AK; Zschaebitz S; Komander C; Jäger D; Haag GM
World J Gastroenterol; 2015 Apr; 21(16):4911-8. PubMed ID: 25945004
[TBL] [Abstract][Full Text] [Related]
13. Controlling Nutritional Status (CONUT) score is a prognostic marker in III-IV NSCLC patients receiving first-line chemotherapy.
Zhang Y; Kong FF; Zhu ZQ; Shan HX
BMC Cancer; 2023 Mar; 23(1):225. PubMed ID: 36894927
[TBL] [Abstract][Full Text] [Related]
14. Class III β-tubulin is a predictive marker for taxane-based chemotherapy in recurrent and metastatic gastric cancer.
Hwang JE; Hong JY; Kim K; Kim SH; Choi WY; Kim MJ; Jung SH; Shim HJ; Bae WK; Hwang EC; Lee KH; Lee JH; Cho SH; Chung IJ
BMC Cancer; 2013 Sep; 13():431. PubMed ID: 24053422
[TBL] [Abstract][Full Text] [Related]
15. Inflammation-based prognostic score predicts survival in patients with advanced gastric cancer receiving biweekly docetaxel and s-1 combination chemotherapy.
Kunisaki C; Takahashi M; Ono HA; Oshima T; Takagawa R; Kimura J; Kosaka T; Makino H; Akiyama H; Endo I
Oncology; 2012; 83(4):183-91. PubMed ID: 22890015
[TBL] [Abstract][Full Text] [Related]
16. Utility of inflammation-based prognostic scoring in patients given systemic chemotherapy first-line for advanced inoperable bladder cancer.
Hwang EC; Hwang IS; Yu HS; Kim SO; Jung SI; Hwang JE; Kang TW; Kwon DD; Park K; Ryu SB
Jpn J Clin Oncol; 2012 Oct; 42(10):955-60. PubMed ID: 22844127
[TBL] [Abstract][Full Text] [Related]
17. Cholinesterase is Associated With Prognosis and Response to Chemotherapy in Advanced Gastric Cancer.
Bi Y; Zhang J; Zeng D; Chen L; Ye W; Yang Q; Ling Y
Pathol Oncol Res; 2021; 27():580800. PubMed ID: 34257526
[No Abstract] [Full Text] [Related]
18. Weight loss and body mass index in advanced gastric cancer patients treated with second-line ramucirumab: a real-life multicentre study.
Parisi A; Cortellini A; Roberto M; Venditti O; Santini D; Dell'Aquila E; Stellato M; Marchetti P; Occhipinti MA; Zoratto F; Mazzuca F; Tinari N; De Tursi M; Iezzi L; Natoli C; Ratti M; Pizzo C; Ghidini M; Porzio G; Ficorella C; Cannita K
J Cancer Res Clin Oncol; 2019 Sep; 145(9):2365-2373. PubMed ID: 31280347
[TBL] [Abstract][Full Text] [Related]
19. Effects of genetic polymorphisms in the ABCB1 gene on clinical outcomes in patients with gastric cancer treated by second-line chemotherapy.
Shitara K; Matsuo K; Ito S; Sawaki A; Kawai H; Yokota T; Takahari D; Shibata T; Ura T; Ito H; Hosono S; Kawase T; Watanabe M; Tajima K; Yatabe Y; Tanaka H; Muro K
Asian Pac J Cancer Prev; 2010; 11(2):447-52. PubMed ID: 20843132
[TBL] [Abstract][Full Text] [Related]
20. Neutrophil count and the inflammation-based glasgow prognostic score predict survival in patients with advanced gastric cancer receiving first-line chemotherapy.
Li QQ; Lu ZH; Yang L; Lu M; Zhang XT; Li J; Zhou J; Wang XC; Gong JF; Gao J; Li J; Li Y; Shen L
Asian Pac J Cancer Prev; 2014; 15(2):945-50. PubMed ID: 24568523
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
